RECURRENT MANTLE CELL LYMPHOMA
Clinical trials for RECURRENT MANTLE CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MANTLE CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT MANTLE CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo attack on lymphoma shows promise in early trial
Disease control CompletedThis early-phase trial tested a three-part treatment for non-Hodgkin lymphoma: freezing tumors (cryoablation), injecting a personalized dendritic cell vaccine made from the patient's own cells, and giving the immunotherapy drug pembrolizumab (Keytruda). The goal was to find the s…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-stage trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goal was to find the safest dose and understand side effects. Researchers also looked at…
Matched conditions: RECURRENT MANTLE CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC